A Single-Dose Study to Evaluate the Effects of ABX-1431 on Gastric Accommodation and Nutrient Volume Tolerance in Patients With Functional Dyspepsia
Phase of Trial: Phase I
Latest Information Update: 14 Dec 2016
At a glance
- Drugs ABX 1431 (Primary)
- Indications Non-ulcer dyspepsia
- Focus Pharmacodynamics
- Sponsors Abide Therapeutics
- 14 Dec 2016 According to an Abide Therapeutics media release, dosing has commenced in this trial.
- 22 Nov 2016 Status changed from not yet recruiting to recruiting.
- 30 Aug 2016 New trial record